These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 24602563)
1. Emerging opportunities for the combination of molecularly targeted drugs with radiotherapy. Searle EJ; Illidge TM; Stratford IJ Clin Oncol (R Coll Radiol); 2014 May; 26(5):266-76. PubMed ID: 24602563 [TBL] [Abstract][Full Text] [Related]
2. Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance? Choy H; Milas L J Natl Cancer Inst; 2003 Oct; 95(19):1440-52. PubMed ID: 14519750 [TBL] [Abstract][Full Text] [Related]
3. Combination of a COX-2 inhibitor with radiotherapy or radiochemotherapy in the treatment of thoracic cancer. Liao Z; Milas L; Komaki R; Stevens C; Cox JD Am J Clin Oncol; 2003 Aug; 26(4):S85-91. PubMed ID: 12902863 [TBL] [Abstract][Full Text] [Related]
4. Radiosensitizers in pancreatic cancer--preclinical and clinical exploits with molecularly targeted agents. Walker AJ; Alcorn SR; Narang AK; Nugent KM; Wild AT; Herman JM; Tran PT Curr Probl Cancer; 2013; 37(5):301-12. PubMed ID: 24331186 [TBL] [Abstract][Full Text] [Related]
5. Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo. Qian M; Qian D; Jing H; Li Y; Ma C; Zhou Y Oncol Rep; 2014 Oct; 32(4):1681-8. PubMed ID: 25328959 [TBL] [Abstract][Full Text] [Related]
6. Celecoxib enhances radiation response of secondary bone tumors of a human non-small cell lung cancer via antiangiogenesis in vivo. Klenke FM; Abdollahi A; Bischof M; Gebhard MM; Ewerbeck V; Huber PE; Sckell A Strahlenther Onkol; 2011 Jan; 187(1):45-51. PubMed ID: 21234531 [TBL] [Abstract][Full Text] [Related]
7. Opportunities and challenges in the era of molecularly targeted agents and radiation therapy. Lin SH; George TJ; Ben-Josef E; Bradley J; Choe KS; Edelman MJ; Guha C; Krishnan S; Lawrence TS; Le QT; Lu B; Mehta M; Peereboom D; Sarkaria J; Seong J; Wang D; Welliver MX; Coleman CN; Vikram B; Yoo S; Chung CH; ; J Natl Cancer Inst; 2013 May; 105(10):686-93. PubMed ID: 23503600 [TBL] [Abstract][Full Text] [Related]
8. Initial experience combining cyclooxygenase-2 inhibition with chemoradiation for locally advanced pancreatic cancer. Crane CH; Mason K; Janjan NA; Milas L Am J Clin Oncol; 2003 Aug; 26(4):S81-4. PubMed ID: 12902862 [TBL] [Abstract][Full Text] [Related]
9. Radiation therapy and molecular-targeted agents in preclinical testing for immunotherapy, brain tumors, and sarcomas: Opportunities and challenges. Vatner R; James CD; Sathiaseelan V; Bondra KM; Kalapurakal JA; Houghton PJ Pediatr Blood Cancer; 2021 May; 68 Suppl 2():e28439. PubMed ID: 32827353 [TBL] [Abstract][Full Text] [Related]
10. Improvement strategies for molecular targeting: Cyclooxygenase-2 inhibitors as radiosensitizers for non-small cell lung cancer. Komaki R; Liao Z; Milas L Semin Oncol; 2004 Feb; 31(1 Suppl 1):47-53. PubMed ID: 14981580 [TBL] [Abstract][Full Text] [Related]
11. Novel targeted radiosensitisers in cancer treatment. Zaidi SH; Huddart RA; Harrington KJ Curr Drug Discov Technol; 2009 Jun; 6(2):103-34. PubMed ID: 19519337 [TBL] [Abstract][Full Text] [Related]
12. [Targeted therapies and radiation therapy in non-small cell lung cancer]. Rivera S; Quéro L; Wong Hee Kam S; Maylin C; Deutsch E; Hennequin C Cancer Radiother; 2011 Oct; 15(6-7):527-35. PubMed ID: 21885318 [TBL] [Abstract][Full Text] [Related]
13. Antitumor and anti-metastatic effects of cyclooxygenase-2 inhibition by celecoxib on human colorectal carcinoma xenografts in nude mouse rectum. Ninomiya I; Nagai N; Oyama K; Hayashi H; Tajima H; Kitagawa H; Fushida S; Fujimura T; Ohta T Oncol Rep; 2012 Sep; 28(3):777-84. PubMed ID: 22751903 [TBL] [Abstract][Full Text] [Related]
14. New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer. Salama JK; Vokes EE J Clin Oncol; 2013 Mar; 31(8):1029-38. PubMed ID: 23401449 [TBL] [Abstract][Full Text] [Related]
15. Recent advances in combined modality therapy. Mierzwa ML; Nyati MK; Morgan MA; Lawrence TS Oncologist; 2010; 15(4):372-81. PubMed ID: 20413642 [TBL] [Abstract][Full Text] [Related]
16. Drug radiotherapy combinations: review of previous failures and reasons for future optimism. Higgins GS; O'Cathail SM; Muschel RJ; McKenna WG Cancer Treat Rev; 2015 Feb; 41(2):105-13. PubMed ID: 25579753 [TBL] [Abstract][Full Text] [Related]
17. Celecoxib enhances the radiosensitizing effect of 7-hydroxystaurosporine (UCN-01) in human lung cancer cell lines. Kim YM; Jeong IH; Pyo H Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e399-407. PubMed ID: 22417802 [TBL] [Abstract][Full Text] [Related]
18. To combine or not combine: the role of radiotherapy and targeted agents in the treatment for renal cell carcinoma. Weiss C; Schulze B; Ottinger A; Rödel C World J Urol; 2014 Feb; 32(1):59-67. PubMed ID: 23652926 [TBL] [Abstract][Full Text] [Related]
19. Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth. Liu W; Chen Y; Wang W; Keng P; Finkelstein J; Hu D; Liang L; Guo M; Fenton B; Okunieff P; Ding I Am J Clin Oncol; 2003 Aug; 26(4):S103-9. PubMed ID: 12902866 [TBL] [Abstract][Full Text] [Related]
20. Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer. Wang L; Chen W; Xie X; He Y; Bai X Exp Oncol; 2008 Mar; 30(1):42-51. PubMed ID: 18438340 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]